

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control nur

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of

Complete if Known			
Application Number	10/090440		
Filing Date	March 4, 2002		
First Named Inventor	Grant McFadden		
Art Unit	1642		
Examiner Name .	M. Yu		
Attorney Docket Number	MDSP-P01-002		

				U.S. PA	TENT DOCUMENTS	
Examiner Initials*		Cite No.1	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document .	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
			Number-Kind Code ² (if known)	MM-DD-YYYY		
		AG*	US-5,770,443-A	06-23-1998	Kiefer et al.	
	T	AH*	US-6,903,195-B1	06-07-2005	Kiefer et al.	
		Al*	US-5,998,131-A	12-07-1999	Barr et al.	
		AJ*	US-6,015,687-A	01-18-2000	Kiefer et al.	
		AK*	US-6,586,395-B1	07-01-2003	Kiefer et al.	
	υ	AL*	US-20030008837-A1	01-09-2003	Kiefer et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶
ns	BA	WO-95/15084	06-08-1995	LXR Biotechnology Inc.	<u> </u>	
<u></u>	BB	WO-96/33416	10-24-1996	LXR Biotechnology Inc.		Г

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was field after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
my	СР	CHITTENDEN et al., Induction of Apoptosis by the BCL-2 Homologue BAK. Nature 374: 733-736, 1995.			
	ca	EVERETT et al., M11L: A Novel Mitochondrial-Localized Protein of Myxoma Virus that Blocks Apoptosis of Infected Leukocytes. Journal of Experimental Medicine 191(9): 1487-1498, 2000.			
	CR	KIEFER et al., Modulation of Apoptosis by the Widely Distributed BCL-2 Homologue BAK. Nature 374: 736-739, 1995.			
V	CS	WANG et al., Myxoma Virus M11L Prevents Apoptosis Through Constitutive Interaction with Bak. Journal of Virology 78(13): 7097-7111, 2004.			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner I	_	7			Date	
		IM I An	∩ <i>171</i> `	~ /	Date	10 11-05
Signature			iu		Considered	10-4-05
	_					

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.